Totonji, S.; Ramos-Triguero, A.; Willmann, D.; Sum, M.; Urban, S.; Bauer, H.; Rieder, A.; Wang, S.; Greschik, H.; Metzger, E.;
et al. Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer. Cancers 2024, 16, 1532.
https://doi.org/10.3390/cancers16081532
AMA Style
Totonji S, Ramos-Triguero A, Willmann D, Sum M, Urban S, Bauer H, Rieder A, Wang S, Greschik H, Metzger E,
et al. Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer. Cancers. 2024; 16(8):1532.
https://doi.org/10.3390/cancers16081532
Chicago/Turabian Style
Totonji, Sainab, Anna Ramos-Triguero, Dominica Willmann, Manuela Sum, Sylvia Urban, Helena Bauer, Astrid Rieder, Sheng Wang, Holger Greschik, Eric Metzger,
and et al. 2024. "Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer" Cancers 16, no. 8: 1532.
https://doi.org/10.3390/cancers16081532
APA Style
Totonji, S., Ramos-Triguero, A., Willmann, D., Sum, M., Urban, S., Bauer, H., Rieder, A., Wang, S., Greschik, H., Metzger, E., & Schüle, R.
(2024). Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer. Cancers, 16(8), 1532.
https://doi.org/10.3390/cancers16081532